EN3285 for the Prevention or Delay of Oral Mucositis in Patients With Head and Neck Cancer

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Oral Mucositis, Head and Neck Cancer

In brief

Randomized, double-blind, placebo-controlled study for the treatment of head and neck cancer(HNC), to assess the ability of EN3285 to prevent or delay the onset of severe oral mucositis(OM).

Key facts

Study ID

NCT00574860

Run by

Endo USA Inc., a Keenova Therapeutics Company

People needed

240

Starts

2007-12-01

Expected to finish

2009-06-01

Last updated by the study team

2013-09-20

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

• Commonwealth ENT — Louisville, Kentucky, United States
• MD Anderson Cancer Center — Houston, Texas, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.